Literature DB >> 20538680

Nail-fold capillary abnormalities are associated with anti-centromere antibody and severity of digital ischaemia.

Ariane L Herrick1, Tonia L Moore, Andrea K Murray, Nina Whidby, Joanne B Manning, Monica Bhushan, Andy Vail.   

Abstract

OBJECTIVES: Advances in nail-fold capillaroscopy allow capillary abnormalities to be quantified. Our aim was to investigate, in patients with SSc, the relationships between the degree of nail-fold capillary abnormality and disease subtypes (lcSSc and dcSSc), duration of RP and the presence of (i) severe digital ischaemia (as defined by previous i.v. vasodilators, debridements or amputations), (ii) a positive ACA, (iii) clinically evident calcinosis, (iv) pulmonary arterial hypertension and (v) telangiectases.
METHODS: This was a retrospective study of 176 patients. Six capillary measurements (four semi-automated and two manual) were calculated (automated width, distance between capillaries, tortuosity and derangement, and manual distance and density). Relationships between these measurements and the different clinical features of SSc were examined using multiple linear regressions (adjusted for age, sex and smoking status).
RESULTS: One hundred and forty-two patients had lcSSc and 34 had dcSSc. Sixty-eight (39%) had a history of severe digital ischaemia, 66 (38%) were anti-centromere positive, 53 (30%) had clinically evident calcinosis and 26 (15%) had an estimated pulmonary artery pressure of >30 mmHg. Positive associations were found between both automated and manually measured distance between capillaries and (i) presence of severe digital ischaemia and (ii) positive ACA, and reduced density was also associated with positive anti-centromere. Patients with moderate/severe telangiectases had wider capillaries compared with those with 'mild' lesions.
CONCLUSIONS: Both severe digital ischaemia and positive ACA are associated with measurable nail-fold capillaroscopic change, which has the potential of being an outcome measure for the structural microvascular disease associated with SSc-spectrum disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538680     DOI: 10.1093/rheumatology/keq139

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  5 in total

1.  Antinuclear antibody-negative systemic sclerosis.

Authors:  Gloria A Salazar; Shervin Assassi; Fredrick Wigley; Laura Hummers; John Varga; Monique Hinchcliff; Dinesh Khanna; Elena Schiopu; Kristine Phillips; Daniel E Furst; Virginia Steen; Murray Baron; Marie Hudson; Suzanne S Taillefer; Janet Pope; Niall Jones; Peter Docherty; Nader A Khalidi; David Robinson; Robert W Simms; Richard M Silver; Tracy M Frech; Barri J Fessler; Jerry A Molitor; Marvin J Fritzler; Barbara M Segal; Firas Al-Kassab; Marilyn Perry; Jeremy Yang; Sara Zamanian; John D Reveille; Frank C Arnett; Claudia Pedroza; Maureen D Mayes
Journal:  Semin Arthritis Rheum       Date:  2014-11-28       Impact factor: 5.532

2.  Pattern of Nailfold Capillaroscopy in Patients With Systemic Lupus Erythematosus.

Authors:  Ting Zhao; Fu-An Lin; Hong-Pu Chen
Journal:  Arch Rheumatol       Date:  2020-04-20       Impact factor: 1.472

Review 3.  Nailfold Capillaroscopy in Rheumatic Diseases: Which Parameters Should Be Evaluated?

Authors:  Mahnaz Etehad Tavakol; Alimohammad Fatemi; Abdolamir Karbalaie; Zahra Emrani; Björn-Erik Erlandsson
Journal:  Biomed Res Int       Date:  2015-09-01       Impact factor: 3.411

4.  Are There Clinical Differences in Limited Systemic Sclerosis according to Extension of Skin Involvement?

Authors:  Marina Scolnik; Luis J Catoggio; Eliana Lancioni; Mirtha R Sabelli; Carla M Saucedo; Josefina Marin; Enrique R Soriano
Journal:  Int J Rheumatol       Date:  2014-11-11

Review 5.  Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases.

Authors:  Liala Moschetti; Silvia Piantoni; Enrico Vizzardi; Edoardo Sciatti; Mauro Riccardi; Franco Franceschini; Ilaria Cavazzana
Journal:  Front Med (Lausanne)       Date:  2022-04-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.